Selexipag

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Selexipag
Selexipag.svg
Names
IUPAC name
2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-(methanesulfonyl)acetamide
Identifiers
475086-01-2 YesY
ChEMBL ChEMBL238804 N
ChemSpider 8089417 YesY
Jmol-3D images Image
KEGG D09994 YesY
PubChem 9913767
UNII 5EXC0E384L YesY
Properties
C26H32N4O4S
Molar mass 496.6 g·mol−1
Except where noted otherwise, data is given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
 N verify (what isYesY/N?)
Infobox references

Selexipag (ACT-293987, NS-304) is a drug currently in development by Actelion as a treatment of pulmonary arterial hypertension. Selexipag and its active metabolite, ACT-333679, are agonists at the PGI2 prostaglandin receptor, which leads to vasodilation in the pulmonary circulation.[1]

References[edit]

  1. ^ Sitbon, O.; Morrell, N. (2012). "Pathways in pulmonary arterial hypertension: The future is here". European Respiratory Review 21 (126): 321–327. doi:10.1183/09059180.00004812. PMID 23204120.  edit